ISPE 2026 年会前瞻:AI 用于计算机化系统验证 CSV 的能力边界与治理
Q-Finity 高级执行顾问 Frank Henrichmann 将在 2026 ISPE 年会上讨论 AI 用于计算机化系统验证(CSV)的机会与风险。他主张把 AI 用于完整性检查、对账核对、缺失引用识别、可追溯性分析和术语一致性审查等可对照源文件客观验证的低风险任务,而评估测试证据是否充分、判定偏差严重性等需要解释判断的活动仍由人负责。
题图:ISPE 官网为本文配的题图(图源:ispe.org)
2026-10-02 | 制药 AI 现场观察 | 主体材料:ISPE 官网新闻(2026-09-30)
来源:ISPE(International Society for Pharmaceutical Engineering)官网新闻,原载 Biosimilar Development(Life Science Connect)
URL:https://www.ispe.org/news/biosimilar-development-covers-2026-ispe-annual-meeting-expo-upcoming-session-ai-enabled
发布日期:2026-09-30
讲者:Frank Henrichmann(Q-Finity 高级执行顾问)
场合:2026 ISPE Annual Meeting & Expo 会议前瞻
As pharmaceutical companies increasingly explore artificial intelligence to support CSV, industry experts are emphasizing that success depends not on blind trust in AI, but on understanding where it adds value and where human oversight remains indispensable. These themes will be explored at the 2026 ISPE Annual Meeting & Expo, where Frank Henrichmann, Senior Executive Consultant at Q-Finity will discuss the opportunities and risks associated with incorporating AI into validation workflows.
随着制药企业越来越多地探索用人工智能支持计算机化系统验证(CSV),行业专家强调:成功不在于对 AI 的盲目信任,而在于分清 AI 在哪里创造价值、人工监督在哪里不可替代。这些主题将在 2026 ISPE 年会暨博览会上展开,Q-Finity 高级执行顾问 Frank Henrichmann 将讨论把 AI 引入验证工作流的机会与风险。
本讲者 Frank Henrichmann,Q-Finity 高级执行顾问(图源:biosimilardevelopment.com)
Henrichmann argues that one of the greatest dangers associated with AI is misplaced confidence. While today's large language models can produce fluent, convincing outputs, their apparent certainty does not necessarily guarantee accuracy. In regulated pharmaceutical environments, that distinction is critical. Rather than viewing AI as a replacement for validation professionals, Henrichmann advocates using it as a tool to automate repetitive, rule-based tasks while preserving human responsibility for interpretation, judgment, and risk-based decision-making.
Henrichmann 认为,与 AI 相关的最大危险之一是错置的自信。如今的大语言模型能产出流畅、令人信服的输出,但表面上的确定并不必然保证准确。在受监管的制药环境里,这个区分至关重要。他反对把 AI 视为验证专业人员的替代品,主张把它当作自动化重复性、规则性任务的工具,同时保留人对解释、判断和基于风险的决策的责任。
According to Henrichmann, the key to determining where AI can be trusted lies in understanding the degree of certainty associated with specific validation activities. Tasks such as completeness checks, reconciliation, identification of missing references, traceability analysis, terminology consistency reviews, and restructuring approved content into required formats can be objectively verified against source documentation. Because these outputs are reproducible and measurable, they represent relatively low-risk applications where AI can provide substantial benefits. In contrast, activities that require interpretation, such as assessing whether test evidence is sufficient, determining the significance of a deviation, or deciding whether a requirement has been adequately implemented, demand human expertise and increased oversight.
在 Henrichmann 看来,判断 AI 哪里可信的关键,在于理解每项验证活动所附带的确定程度。完整性检查、对账核对、缺失引用识别、可追溯性分析、术语一致性审查,以及把已批准内容重组为规定格式等任务,可以对照源文件客观验证;这些输出可复现、可度量,属于风险相对较低、AI 能带来实质收益的应用。相反,需要解释判断的活动(比如评估测试证据是否充分、判定偏差的严重性、决定某项要求是否已被充分落实)则需要人的专业知识与更强的监督。
A recurring theme throughout the discussion is that human review alone is not enough to ensure quality. Henrichmann cautions against relying solely on the concept of a "human in the loop," noting that psychological factors can undermine the effectiveness of oversight. He highlights three well-documented risks: automation bias, in which users place excessive trust in machine-generated recommendations; cognitive ease, where polished and well-organized information appears more credible than it actually is; and review fatigue, which can occur when personnel assess large volumes of mostly accurate output. These factors can make it difficult for reviewers to detect subtle errors hidden within otherwise convincing AI-generated content.
贯穿整场讨论的一个反复出现的主题是:仅靠人工复核不足以保证质量。Henrichmann 提醒不要只依赖“人在环路”这一概念,并指出心理因素会侵蚀监督的有效性。他点名三个有充分记录的风险:自动化偏误,即用户过度信任机器生成的建议;认知顺畅,即打磨得整洁有序的信息显得比实际更可信;复核疲劳,即当人员面对大量大体正确的输出时产生。这些因素会让复核者难以发现藏在有说服力的 AI 生成内容里的细微错误。
To address these challenges, Henrichmann recommends implementing independent technical controls and procedural guardrails alongside human review. Effective AI governance should define what information a tool can access, what outputs it may generate, and under what circumstances it must escalate decisions to qualified personnel. These safeguards help ensure that AI remains a support tool rather than becoming an uncontrolled source of compliance risk.
为应对这些挑战,Henrichmann 建议在人工复核之外并行实施独立的技术控制与程序性护栏。有效的 AI 治理应当界定:工具可以访问什么信息、可以生成什么输出、在什么情形下必须把决策上报给有资质的人员。这些保障有助于确保 AI 始终是支持工具,而不是失控的合规风险来源。
One area where AI is already demonstrating practical value is automated test case generation. By leveraging approved requirements, functional specifications, risk assessments, system configurations, standard operating procedures, and historical validation data, AI systems can generate draft test cases containing preconditions, test steps, expected results, acceptance criteria, and evidence requirements. However, Henrichmann stresses that success depends heavily on the quality of the underlying inputs. Poorly written requirements will inevitably produce incomplete or inadequate validation outputs regardless of the sophistication of the AI model. In his view, the quality ceiling for AI-generated validation artifacts is determined by the quality of the source data and requirements rather than by the technology itself.
AI 已经展现实际价值的一个领域是自动化测试用例生成。借助已批准的需求、功能规格、风险评估、系统配置、标准操作规程和历史验证数据,AI 系统能生成包含前置条件、测试步骤、预期结果、接受标准与证据要求的测试用例草案。但 Henrichmann 强调,成败高度依赖底层输入的质量。写得糟糕的需求,无论 AI 模型多复杂,都必然产出不完整或不适格的验证输出。在他看来,AI 生成验证产物的质量上限由源数据和需求的质量决定,而不是由技术本身决定。
AI is also transforming traceability management, an area that has traditionally required extensive manual effort. Henrichmann describes the emergence of "traceability agents" capable of analyzing lifecycle documentation and automatically identifying orphan requirements, broken document links, inconsistent identifiers, and downstream artifacts affected by requirement changes. These capabilities significantly improve maintenance and structural accuracy. However, he warns that traceability completeness does not automatically guarantee validation adequacy. An AI system may successfully connect a requirement to a related test case while failing to recognize that the test itself lacks sufficient depth to verify the requirement properly. Consequently, experts must continue evaluating the substance of validation evidence rather than relying on formally complete documentation.
AI 也在改变可追溯性管理(一个传统上耗费大量人力的领域)。Henrichmann 描述了“追溯智能体”的兴起:它们能分析生命周期文档,自动识别孤儿需求、断裂的文档链接、不一致的标识符,以及受需求变更影响的下游产物。这些能力显著改善了维护效率和结构准确性。但他警告,追溯的完整并不自动等于验证的充分。AI 系统可能成功把某条需求连到相关测试用例,却识别不出该测试本身深度不足、无法真正验证这条需求。因此,专家仍须持续评估验证证据的实质内容,而不是依赖形式上完整的文档。
Looking ahead, Henrichmann sees validation professionals evolving from document managers into what he calls "quality architects." As AI automates many administrative activities, validation specialists will increasingly focus on defining intended use, developing precise requirements, structuring risk assessments, and critically reviewing AI-generated outputs. Rather than spending their days manually assembling compliance documentation, professionals will devote more time to designing systems and processes that produce compliance by design. This shift aligns closely with the principles of ISPE GAMP® 5 Guide (Second Edition), which emphasizes critical thinking and risk-based decision-making over purely procedural approaches.
展望未来,Henrichmann 认为验证专业人员将从文档管理者演进为他所说的“质量架构师”。随着 AI 自动化大量事务性工作,验证专家将越来越多地把精力放在定义预期用途、编写精确的需求、构建风险评估、批判性审查 AI 生成的输出上。专业人士不再把日子花在手工拼装合规文档上,而是把更多时间用于设计“合规内生于设计”的系统与流程。这一转变与 ISPE GAMP® 5 指南(第二版)的原则高度一致:该指南强调批判性思维和基于风险的决策,而非纯程序化的做法。
Training and process design will also play a critical role in safe AI adoption. Henrichmann argues that organizations should redesign workflows to limit review volume, prioritize attention through risk-based review triggers, and introduce mechanisms that require active engagement from reviewers. Examples include requiring written review justifications, rotating reviewers, and incorporating peer reviews rather than allowing simple approval clicks. Organizations should also routinely measure how many errors are detected and how many slip through validation controls, ensuring that oversight mechanisms remain effective over time.
培训与流程设计在 AI 安全落地中同样扮演关键角色。Henrichmann 主张,组织应重新设计工作流以限制复核量、通过基于风险的复核触发器给注意力排优先级,并引入要求复核者主动投入的机制。例子包括:要求书面的复核理由、轮换复核人、引入同行复核,而不是允许简单的“点击批准”。组织还应定期度量检出了多少错误、又有多少漏过验证控制,确保监督机制长期保持有效。
Despite growing enthusiasm surrounding AI, Henrichmann cautions that some highly publicized capabilities remain largely unproven. To the best of his knowledge, he notes that fully autonomous "self-validating" systems do not yet exist in practical pharmaceutical applications, and approaches in which one AI system simply reviews the work of another may create a false sense of security if both models share similar blind spots. While AI can dramatically improve productivity and testing coverage, claims of complete automation or 100 percent validation coverage remain unrealistic. Current success stories are generally less glamorous but highly valuable, including document drafting, completeness reviews, consistency checks, gap identification, and first-pass test script generation.
尽管围绕 AI 的热情不断升温,Henrichmann 提醒,一些被高调宣传的能力在很大程度上仍未被证实。就他所知,完全自主的“自我验证”系统在制药实际应用中尚不存在;让一个 AI 系统复核另一个 AI 的工作,如果两个模型有相似的盲区,只会制造虚假的安全感。AI 能大幅提升生产力和测试覆盖率,但“完全自动化”或“100% 验证覆盖率”的说法仍不现实。当下的成功案例通常不那么炫目但极有价值:文档起草、完整性复核、一致性检查、差距识别,以及测试脚本的首稿生成。
Henrichmann ultimately believes AI is fully compatible with the principles outlined in the ISPE GAMP 5 Guide (Second Edition), provided organizations apply it thoughtfully. AI can support risk-based decision-making by drawing from broader pools of historical information and improving consistency across projects. However, if companies simply use AI to accelerate template-driven documentation practices without improving critical thinking, they risk scaling inefficient validation processes rather than transforming them.
Henrichmann 最终认为,只要组织审慎使用,AI 与 ISPE GAMP 5 指南(第二版)所述原则完全兼容。AI 可以通过调用更宽的历史信息池、改善跨项目的一致性来支持基于风险的决策。但如果企业只是用 AI 加速模板驱动的文档做法而不改进批判性思维,其结果可能是把低效的验证流程放大,而不是改造它。
For organizations beginning their AI journey, Henrichmann recommends improving requirements quality before investing in new technologies, conducting parallel pilot projects using previously completed validation packages, establishing AI literacy training, implementing governance policies early, and involving quality assurance teams from the outset. These practical steps, which will be discussed further at the 2026 ISPE Annual Meeting & Expo, can help pharmaceutical manufacturers build trust in AI while maintaining the rigorous compliance standards required for computerized system validation.
对刚启动 AI 之旅的组织,Henrichmann 建议:先改进需求质量再投资新技术;用既往已完成的验证包做平行试点项目;建立 AI 素养培训;尽早实施治理政策;从一开始就让质量保证团队参与。这些务实步骤将在 2026 ISPE 年会暨博览会上进一步讨论,能帮助制药制造商在维持计算机化系统验证所需严格合规标准的同时,建立起对 AI 的信任。
资料来源:
ISPE 官网新闻:Biosimilar Development Covers 2026 ISPE Annual Meeting & Expo Upcoming Session, AI-Enabled Computerized System Validation (CSV),2026-09-30,ispe.org(原载 Biosimilar Development / Life Science Connect)
2026 ISPE Annual Meeting & Expo 会议页:ispe.org/conferences/2026-annual-meeting-expo
来源:小南AI实验室 · mp.weixin.qq.com